| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/11/2009 | US7572883 Somatostatin-dopamine chimeric analogs |
| 08/11/2009 | US7572882 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions |
| 08/11/2009 | US7572788 Compositions and methods relating to novel compounds and targets thereof |
| 08/11/2009 | US7572772 Use preventing transplant rejection, treating autoimmune diseases, and in leukocyte typing and FAC sorting; CD28/CTLA4Ig fusion proteins |
| 08/11/2009 | US7572771 Mimetic that promotes ABCA1-dependent lipid efflux from cells and is substantially non-cytotoxic; dyslipidemic and cardiovascular disorders such as atherosclerosis; ATP-binding cassette transporter A1 (ABCA1) |
| 08/11/2009 | US7572770 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 08/11/2009 | US7572768 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 08/11/2009 | US7572765 polypeptides or fragments used for treating bone disorders such as osteoporosis |
| 08/11/2009 | US7572764 Uses of chemically-modified cholinesterases for detoxification of organophosporus compounds |
| 08/11/2009 | US7572763 Controlling cell differentiation; muscular disorders |
| 08/11/2009 | US7572762 Materials and methods relating to the induction of apoptosis in target cells |
| 08/11/2009 | US7572628 Eukaryotic layered vector initiation systems |
| 08/11/2009 | US7572619 Using immortalized trangenic cell to express antihemophilic factor and blood coagulation factor IX for treatment of blood disorders |
| 08/11/2009 | US7572613 Drug delivery system for accelerated subcutaneous absorption |
| 08/11/2009 | US7572599 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 08/11/2009 | US7572594 Screening assays for agonists or antagonists or receptor activator of NF-κB |
| 08/11/2009 | US7572591 Thrombotic thrombocytopenic purpura (TTP); epitope recognized by an antibody (anti-ADAMTS-13 antibody) against a cleaving protease ( ADAMTS-13) specific to von Willebrand factor |
| 08/11/2009 | US7572580 Promoter variants of the alpha-7 nicotinic acetylcholine receptor |
| 08/11/2009 | US7572465 Isolated material having an anti-organotrophic effect |
| 08/11/2009 | US7572454 From Canine Distemper Virus; vaccines; luteinizing hormone releasing hormone |
| 08/11/2009 | US7572452 Utilizing polypeptide (p43) of amino acid sequence 1; inducting macrophage monocyte and endothelial cell reepithelization, proliferation of fibroblasts and/or angiogenesis; topical skin treatment |
| 08/11/2009 | US7572450 Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins |
| 08/11/2009 | US7572447 Methods and compositions for selective modulation of vascularization |
| 08/11/2009 | US7572446 Antagonists of HMG1 for treating inflammatory conditions |
| 08/11/2009 | US7572440 Method for repairing a defect in an intervertebral disc |
| 08/11/2009 | US7572439 Disinfecting or sterilizing a surface of prosthetic device or catheter, preventing or breaking a bacterial biofilm growth, administering bactericide enzyme lysostaphin |
| 08/11/2009 | US7572438 Mutant having uracil phosphoribosyl transferase activity |
| 08/11/2009 | US7572437 Long acting human interferon analogs |
| 08/11/2009 | US7572436 Thionin as an antineoplastic and immunostimulant |
| 08/11/2009 | US7572434 In drosophila, aplysia, and rodents; one isoform (dcreb2-a) encodes a cyclic 3',5'-adenosine monophosphate (camp)-responsive transcriptional activator, another isoform (dcreb2-b) codes for an antagonist which blocks the activator |
| 08/11/2009 | CA2408535C Compositions comprising dendrimer complexes |
| 08/11/2009 | CA2348732C Human h37 proteins and cdnas encoding the same |
| 08/11/2009 | CA2328133C Factors affecting tumor necrosis factor receptor releasing enzyme activity |
| 08/11/2009 | CA2327254C Chemically modified mutant enzymes and methods for producing them and screening them |
| 08/11/2009 | CA2321263C Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 08/11/2009 | CA2287521C Human recombinant beta-interferon with improved solubility |
| 08/11/2009 | CA2271248C Use of a notch ligand in immunotherapy |
| 08/11/2009 | CA2258503C Lectin compositions and uses thereof |
| 08/11/2009 | CA2241572C Apo-2 ligand |
| 08/11/2009 | CA2236699C Immunity against actinobacillus pleuropneumoniae's rtx toxins apx |
| 08/11/2009 | CA2224404C Cell volume-regulated human kinase h-sgk |
| 08/06/2009 | WO2009097587A2 Nanoscale bound bilayers, methods of use and production |
| 08/06/2009 | WO2009097508A2 Methods and compositions for wound healing |
| 08/06/2009 | WO2009097394A2 Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
| 08/06/2009 | WO2009097332A2 Therapeutic compositions comprising an amine-containing lipid and a protein |
| 08/06/2009 | WO2009097128A1 Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
| 08/06/2009 | WO2009096425A1 Neovascularization-promoting factor |
| 08/06/2009 | WO2009095916A2 Cd14 and peptides thereof for protection of cells against cell death |
| 08/06/2009 | WO2009095796A2 Tapasin augmentation for enhanced immune response |
| 08/06/2009 | WO2009095790A1 Preparation of terminally-sterilized collagen that is soluble at neutral ph |
| 08/06/2009 | WO2009095646A2 Peptides from factor viii |
| 08/06/2009 | WO2009095500A1 Inhibitors of lentiviral replication |
| 08/06/2009 | WO2009095480A1 Improved antitumoral treatments |
| 08/06/2009 | WO2009095453A1 Treatment of microbial infections |
| 08/06/2009 | WO2009095450A1 Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers |
| 08/06/2009 | WO2009095372A1 Methods and compositions using klotho-fgf fusion polypeptides |
| 08/06/2009 | WO2009095265A1 The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| 08/06/2009 | WO2009095261A2 Vaccine compositions |
| 08/06/2009 | WO2009095033A1 Vaccine compositons |
| 08/06/2009 | WO2009094850A1 Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof |
| 08/06/2009 | WO2009094846A1 Insulin nasal powder inhalation |
| 08/06/2009 | WO2009094742A1 Toxin of the spider phoneutria nigriventer for treatment of erectile dysfunction |
| 08/06/2009 | WO2009094718A1 Methods of treating thromboembolic disorders |
| 08/06/2009 | WO2009079220A3 Recombinant elastase proteins and methods of manufacturing and use thereof |
| 08/06/2009 | WO2009073146A3 Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| 08/06/2009 | WO2009068689A3 Combination of protein tyrosine phosphatase inhibitors and human growth hormone for the treatment of muscle atrophy and related disorders |
| 08/06/2009 | WO2009068602A3 Oral care compositions comprising casein, ovalbumin, whey or soy protein |
| 08/06/2009 | WO2009060452A3 Methods and compositions for treating biliary cholesterol crystallization and related conditions |
| 08/06/2009 | WO2009051717A3 Human factor ix variants with an extended half life |
| 08/06/2009 | WO2009049914A3 Novel patient subgroups for thrombolysis |
| 08/06/2009 | WO2009043522A3 Use of a peptide as a therapeutic agent |
| 08/06/2009 | WO2009043463A3 Use of gluten exorphin c : as a therapeutic agent |
| 08/06/2009 | WO2009040086A3 Use of salusin-alpha as a therapeutic agent |
| 08/06/2009 | WO2009036149A3 Methods for treatment of degenerative disease associated with apoptosis |
| 08/06/2009 | WO2009035497A3 Disease related cysteine modifications and uses thereof |
| 08/06/2009 | WO2009033795A3 Use of a obestatin as a therapeutic agent |
| 08/06/2009 | WO2009033794A3 Use of endothelin-1, optionally in combination with obestatin, as a therapeutic agent |
| 08/06/2009 | WO2009033793A3 Pentagastrin as a therapeutic agent |
| 08/06/2009 | WO2009033721A3 Use of salusin beta alone or in combination with octreotide as a therapeutic agent |
| 08/06/2009 | WO2008138131A9 Bone targeted alkaline phosphatase, kits and methods of use thereof |
| 08/06/2009 | WO2008124102A3 Ara-c in combination with a cytokine-secreting cell and use thereof |
| 08/06/2009 | WO2008109433A8 Anti-angiogenic peptides |
| 08/06/2009 | WO2008100450A4 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 08/06/2009 | WO2008095015A8 Method of treating recurrent tumors |
| 08/06/2009 | WO2008086449A8 Synthetic osteopontin peptides and methods of use |
| 08/06/2009 | WO2008052165A8 Method for treating pathological pulmonary conditions and bleomycin associated pulmonary fibrosis |
| 08/06/2009 | WO2008051818A8 Spontaneously forming ellipsoidal phospholipid unilamellar vesicles |
| 08/06/2009 | WO2008022253A8 An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
| 08/06/2009 | WO2007149875A8 Compositions and methods for treating, preventing and/or reversing type-1 diabetes |
| 08/06/2009 | WO2004009778A3 Kinases and phosphatases |
| 08/06/2009 | WO2002074782A3 Isolation and purification procedure of vasopeptidase peptide inhibitors |
| 08/06/2009 | US20090199306 Fucosyl transferase gene |
| 08/06/2009 | US20090198145 Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| 08/06/2009 | US20090198047 2'-Modified Oligonucleotides |
| 08/06/2009 | US20090197821 Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment |
| 08/06/2009 | US20090197817 Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors |
| 08/06/2009 | US20090197816 Stabilizing Alkylglycoside Compositions and Methods Thereof |
| 08/06/2009 | US20090197815 Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist |
| 08/06/2009 | US20090197814 Chemically modified peptides derived from the chemokine CCL14 (HCC-1); replacement of the ultimate N-terminal amino acid of CCL14[9-74] by nonanoic acid (NNY) converts it into a potent agonist; inactivation of the chemokine receptor; antiinflammatory agents |
| 08/06/2009 | US20090197813 Methods for treating FSH related conditions with GnRH antagonists |